Home LiteratureArticle Details
PMID: 16799634 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.

Oncogene ·Vol. 26 ·No. 1 ·2007-01-04 ·Pages 77-90

Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW

Abstract

The epigenetic silencing of tumor suppressor genes is a common event during carcinogenesis, and often involves aberrant DNA methylation and histone modification of gene regulatory regions, resulting in the formation of a transcriptionally repressive chromatin state. Two examples include the antimetastatic, tumor suppressor genes, desmocollin 3 (DSC3) and MASPIN, which are frequently silenced in this manner in human breast cancer. Treatment of the breast tumor cell lines MDA-MB-231 and UACC 1179 with 5-aza-2'-deoxycytidine (5-aza-CdR) induced transcriptional reactivation of both genes in a dose-dependent manner. Importantly, DSC3 and MASPIN reactivation was closely and consistently linked with significant decreases in promoter H3 K9 di-methylation. Moreover, 5-aza-CdR treatment also resulted in global decreases in H3 K9 di-methylation, an effect that was linked to its ability to mediate dose-dependent, post-transcriptional decreases in the key enzyme responsible for this epigenetic modification, G9A. Finally, small interfering RNA (siRNA)-mediated knockdown of G9A and DNMT1 led to increased MASPIN expression in MDA-MB-231 cells, to levels that were supra-additive, verifying the importance of these enzymes in maintaining multiple layers of epigenetic repression in breast tumor cells. These results highlight an additional, complimentary mechanism of action for 5-aza-CdR in the reactivation of epigenetically silenced genes, in a manner that is independent of its effects on DNA methylation, further supporting an important role for H3 K9 methylation in the aberrant repression of tumor suppressor genes in human cancer.

MeSH Terms
Azacitidine/analogs & derivatives,pharmacology Cell Line, Tumor Decitabine Enzyme Inhibitors/pharmacology Genes, Tumor Suppressor Histone Methyltransferases Histone-Lysine N-Methyltransferase/antagonists & inhibitors Histones/metabolism Humans Methylation Protein Methyltransferases Reverse Transcriptase Polymerase Chain Reaction
Chemicals
Enzyme Inhibitors Histones Decitabine Histone Methyltransferases Protein Methyltransferases Histone-Lysine N-Methyltransferase Azacitidine
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Wozniak R J
Department of Pharmacology and Toxicology, Arizona Cancer Center, University of Arizona, Tucson, AZ 85724-5024, USA.
Klimecki W T
Lau S S
Feinstein Y
Futscher B W
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
0950-9232
Published
2007-01-04
Epub
2006-00-26
Pages
77-90
Language
English
Region
England
NLM ID
8711562
Subset
IM
Grants
NCI NIH HHS · CA65662 · United States
NCI NIH HHS · T32-CA09213 · United States
NIEHS NIH HHS · T32 ES007091 · United States
NIEHS NIH HHS · P30 ES006694 · United States
NIEHS NIH HHS · P30 ES06694 · United States
NCI NIH HHS · R01 CA065662 · United States
PHS HHS · P30023074 · United States
NIEHS NIH HHS · ES007091 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com